The Institut de la Màcula, the first Spanish centre to treat a patient in the TREND Study

Last Wednesday, 18 March, the Institut de la Màcula became the first Spanish centre to treat a patient using a pre-filled syringe as part of the TREND Study.

The Study aims to demonstrate that the efficacy and safety of ranibizumab (0.5mm) in a Treat-and-Extend protocol is no less than the monthly injection protocol for the treatment of age-related macular degeneration (AMD) of a wet or exudative type.

Up to now, the medicine Lucentis has been presented in a vial and has required filling. In this trial, for the first time in Spain, Lucentis is provided in a pre-filled syringe.

TREND is an international study being carried out in 20 countries, including Germany, Denmark, Italy, Portugal and the United Kingdom. Only six centres are taking part in Spain, with the Institut de la Màcula being the first in the country to test it.

At present, the Institut de la Màcula is working on a programme of clinical trials in the initial phase or that of the recruitment of patients affected by ophthalmological pathologies, especially those of the retina. These trials enable us to investigate new treatments with today’s most innovative drugs and technology.